Skip to main content
. Author manuscript; available in PMC: 2022 Apr 7.
Published in final edited form as: Adv Exp Med Biol. 2021;1322:115–138. doi: 10.1007/978-981-16-0267-2_5

Table 5.4.

Entry Inhibitor in development

Drug Route Dose Company Clinical trial phase ClinicalTrials.gov identifier
Bulevirtide (myrcludex B) Parenteral 2–5 mg SC qd 48 weeks Hepatera, Russia with MYR GmbH, Germany 2b NCT02888106